Patents by Inventor Ingrid Maurer-Fogy
Ingrid Maurer-Fogy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7282483Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: October 16, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7264944Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: March 15, 2000Date of Patent: September 4, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7238776Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: July 3, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020183485Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: February 23, 2001Publication date: December 5, 2002Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020169118Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: November 14, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020155112Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: October 24, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6440693Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 2002Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020090676Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: July 11, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6417158Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: July 9, 2002Assignee: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6294352Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequence can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: February 1, 1995Date of Patent: September 25, 2001Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6271346Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: August 7, 2001Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6221675Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF is receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: April 24, 2001Assignee: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 5843791Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: December 1, 1998Assignee: Amgen Boulder Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 5837842Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.Type: GrantFiled: January 23, 1995Date of Patent: November 17, 1998Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
-
Patent number: 5710027Abstract: Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.Type: GrantFiled: May 26, 1994Date of Patent: January 20, 1998Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Edgar Falkner, Gerhard Bodo, Tilman Voss, Ingrid Maurer-Fogy
-
Patent number: 5589371Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: March 30, 1995Date of Patent: December 31, 1996Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5559025Abstract: The invention relates to the expression of mature HRV proteinase 2A, the partial purification thereof and the preparation of substrates having an inhibitory effect.Type: GrantFiled: October 11, 1994Date of Patent: September 24, 1996Assignee: Boehringer Ingelheim International GmbHInventors: Horst Ahorn, Ingrid Maurer-Fogy, Wolfgang Sommergruber, Andreas Zophel, Dieter Blaas, Ernst Kuchler, Hans-Dieter Liebig, Timothy Skern
-
Patent number: 5436162Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: September 15, 1992Date of Patent: July 25, 1995Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5260204Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: September 15, 1992Date of Patent: November 9, 1993Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5240847Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: March 11, 1988Date of Patent: August 31, 1993Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann